Celgene Corp (CELG) 155.51 $CELG
Final Glance: Biotechnology companies
AP - Tue Jun 03, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bargains in Biotech? Yes, They Exist
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 03, 5:00PM CDT
Bargains in biotech? Isn't that an awfully good example of an oxymoron? Not according to a new study conducted by Richard Evans, a longtime Wall Street analyst. The study focuses on something that is inherently difficult: valuing a company's...
Midday Glance: Biotechnology companies
AP - Tue Jun 03, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Jun 03, 10:20AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
Stock Market News for June 02, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 9:06AM CDT
Benchmarks ended Friday’s trading session little changed following mixed economic reports
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Business Wire - Sun Jun 01, 8:00AM CDT
Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead
Todd Campbell, The Motley Fool - Motley Fool - Thu May 29, 5:30PM CDT
AstraZeneca played hard to get and won, at least for now. The British pharmaceutical major this month rejected two nine-figure buyout offers from Pfizer , which now must wait at least three months before making any additional offers. ...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Stocks Slightly Higher Amid Mixed Data; S&P 500 Logs New High
at Investor's Business Daily - Thu May 29, 9:32AM CDT
Stocks opened modestly higher Thursday despite mixed economic data. The Nasdaq climbed 0.4% to its best levels since early April. The S&P 500 rose 0.2% to a record high. Meanwhile, the Dow Jones industrial average ticked up 0.1%. Volume was tracking...
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.
How Will Celgene (CELG) Stock Be Affected By This Analyst Action?
at The Street - Thu May 29, 7:17AM CDT
Shares of Celgene (CELG) are lower after J.P. Morgan (JPM) downgraded the stock to 'neutral' from 'overweight' and lowered its price target to $170. from $180.
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
Final Glance: Biotechnology companies
AP - Tue Jun 03, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bargains in Biotech? Yes, They Exist
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 03, 5:00PM CDT
Bargains in biotech? Isn't that an awfully good example of an oxymoron? Not according to a new study conducted by Richard Evans, a longtime Wall Street analyst. The study focuses on something that is inherently difficult: valuing a company's...
Midday Glance: Biotechnology companies
AP - Tue Jun 03, 12:30PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Jun 03, 10:20AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
Stock Market News for June 02, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 9:06AM CDT
Benchmarks ended Friday’s trading session little changed following mixed economic reports
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented at ASCO 2014
Business Wire - Sun Jun 01, 8:00AM CDT
Celgene Corporation (NASDAQ: CELG) today announced updated Overall Survival (OS) results from a post-hoc analysis of its phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer. A poster discussion of the analysis is scheduled for Sunday, June 1st at 11:30 am CT at the 50th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill.
Biogen Idec
at Investor's Business Daily - Thu May 29, 5:48PM CDT
Biogen Idec (BIIB) rose 4% after JPMorgan upgraded its stock to overweight from neutral, citing positive opinions on oral multiple-sclerosis drug Tecfidera, and hiked its price target to 375 from 300. JPMorgan cut Celgene (CELG) to neutral from...
Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead
Todd Campbell, The Motley Fool - Motley Fool - Thu May 29, 5:30PM CDT
AstraZeneca played hard to get and won, at least for now. The British pharmaceutical major this month rejected two nine-figure buyout offers from Pfizer , which now must wait at least three months before making any additional offers. ...
Array BioPharma Collaborates with Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 4:10PM CDT
Array BioPharma (ARRY) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec (BIIB).
Biogen Upgraded, Celgene Downgraded On Pipelines
at Investor's Business Daily - Thu May 29, 2:18PM CDT
Big-cap biotechs Biogen Idec (BIIB) and Celgene (CELG) were headed in opposite directions on the stock market today after JPMorgan upgraded one and downgraded the other. JPMorgan analyst Geoff Meacham lifted his rating on Biogen to overweight from...
Stocks Slightly Higher Amid Mixed Data; S&P 500 Logs New High
at Investor's Business Daily - Thu May 29, 9:32AM CDT
Stocks opened modestly higher Thursday despite mixed economic data. The Nasdaq climbed 0.4% to its best levels since early April. The S&P 500 rose 0.2% to a record high. Meanwhile, the Dow Jones industrial average ticked up 0.1%. Volume was tracking...
Veracyte, Foundation Medicine and Panacea Global Paving Way in Faster, More Accurate Cancer Diagnostics
ACCESSWIRE - Thu May 29, 8:53AM CDT
Whitefish, MT / May 29, 2014 / Most of the science behind disease is only truly understandable by scientists, researchers, and physicians rather than the general population. What everyone does understand is that, in virtually every scenario, early detection is a key to treatment or even survivorship. The life sciences IPO boom that started in 2013 has created some additional wind under the sails of few diagnostics companies, including Veracyte Inc. (NASDAQ: VCYT) and Foundation Medicine Inc. (NASDAQ: FMI), and it should have investors taking a closer look at upstart Panacea Global, Inc. (OTCQB: PANG) and its new cancer-detecting technology.
How Will Celgene (CELG) Stock Be Affected By This Analyst Action?
at The Street - Thu May 29, 7:17AM CDT
Shares of Celgene (CELG) are lower after J.P. Morgan (JPM) downgraded the stock to 'neutral' from 'overweight' and lowered its price target to $170. from $180.
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
